The addition of immunotherapy consisting of nivolumab (Opdivo) and ipilimumab (Yervoy) to lutetium-177-PSMA (Pluvicto) exhibited enhanced efficacy outcomes vs the radioligand alone as a treatment for patients with advanced castration-resistant…
The addition of immunotherapy consisting of nivolumab (Opdivo) and ipilimumab (Yervoy) to lutetium-177-PSMA (Pluvicto) exhibited enhanced efficacy outcomes vs the radioligand alone as a treatment for patients with advanced castration-resistant…